- Users can connect, reconnect and disconnect even when flow path is wet and pressurized
- New Lynx® CDR connectors facilitate faster and more economic biopharma fluid management
BILLERICA, Mass., April 26, 2016 /PRNewswire/ -- MilliporeSigma today announced the launch of its first-in-class Lynx® CDR connectors to improve fluid management in the biopharma industry. The Lynx® CDR connectors debut at the International Pharmaceutical Expo (INTERPHEX) event in New York, New York, April 26-28.
"Lynx® CDR connectors will change the way pharmaceutical fluids are managed, lowering drug manufacturing costs," said Udit Batra, CEO, MilliporeSigma. "Our connectors set a new standard for sterile fluid connections, dramatically improving ease of use and reliability."
Making simple, reliable, sterile-to-sterile fluid connections is critical to successful biomanufacturing. Previous disposable connector technology allowed users to make only a single sterile connection per device, requiring the use of multiple devices per unit operation. Previous technology also required a dry, non-pressurized flow path during connection and disconnection. These limitations are resource- and cost-intensive when industry standards demand increased productivity and improved efficiency at all stages of the drug manufacturing process. With the Lynx® CDR connectors, users can perform faster, more economic fluid management when the flow path is wet and pressurized.
Lynx® CDR connectors allow efficient fluid management through sterile connection, disconnection and reconnection giving customers a fail-safe alternative to the time-consuming tube welding processes and costly manifold configurations traditionally used in upstream and downstream processing. The connectors provide efficient fluid management with six sterile connections, disconnections and reconnections from one disposable device.
INTERPHEX attendees should visit booth #2841 to learn more about MilliporeSigma's products and speak with company experts. Follow us on Twitter @MilliporeSigma.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 72 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $130 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany operates as EMD Serono, MilliporeSigma and EMD Performance Materials in the U.S. and Canada.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.